Tesaro Inc. (TSRO) 43.30 $TSRO Noteworthy Thursday

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Tesaro Inc. (TSRO) 43.30 $TSRO

Noteworthy Thursday Option Activity: TSRO, MRVL, AKS
DividendChannel.com - Thu Jun 16, 2:35PM CDT
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Tesaro Inc , where a total volume of 2,802 contracts has been traded thus far today, a contract volume which is representative of...
TSRO: 43.30 (+0.83)

TESARO Provides Pipeline Update at ASCO Investor Briefing
GlobeNewswire - Sat Jun 04, 6:00PM CDT
-- Rolapitant IV NDA accepted for review by FDA; PDUFA date is January 11, 2017
TSRO: 43.30 (+0.83)

AWS Morning Technical Breakdown Highlights: bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro
ACCESSWIRE - Mon May 23, 8:18AM CDT
LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro.
BLUE: 40.45 (+0.23), SQNM: 1.09 (-0.03), TSRO: 43.30 (+0.83), NKTR: 15.21 (+0.12)

TESARO Congratulates Dr. Mary Lynne Hedley on Being Named Life Science "Entrepreneur of the Year" by the New England Venture Capital Association
GlobeNewswire - Thu May 19, 4:46PM CDT
TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to congratulate co-founder, President and COO Dr. Mary Lynne Hedley on being named the Life Science "Entrepreneur of the Year" by the New England Venture Capital Association. The 2016 NEVY Awards celebrate New England's Life Science and Tech communities.
TSRO: 43.30 (+0.83)

TESARO Announces Five Abstracts to be Presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire - Wed May 18, 4:30PM CDT
TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of five abstracts at the 2016 American Society of Clinical Oncology (ASCO) annual meeting, June 3 to June 7, 2016, in Chicago. In addition, TESARO will host an investor and analyst briefing in Chicago on Saturday, June 4 at 6:15 PM local time in conjunction with the ASCO annual meeting.
TSRO: 43.30 (+0.83)

WuXi Biologics Congratulates TESARO for Anti-TIM-3 Antibody IND Submission in the U.S.
PR Newswire - Tue May 10, 7:00AM CDT
WuXi Biologics (WuXi), a leading open-access R&D capability and technology platform company dedicated to biologics and a WuXi AppTec company, announced today that its partner TESARO submitted an Investigational New Drug (IND) Application for TSR-022 to the U.S. Food and Drug Administration.
TSRO: 43.30 (+0.83)

Tesaro reports 1Q loss
Automated Insights - Thu May 05, 6:21PM CDT
WALTHAM, Mass. (AP) _ Tesaro Inc. (TSRO) on Thursday reported a loss of $90.8 million in its first quarter.
TSRO: 43.30 (+0.83)

TESARO Announces First-Quarter 2016 Operating Results
GlobeNewswire - Thu May 05, 3:06PM CDT
-- U.S. launch of VARUBI(R) underway; New Drug Application (NDA) for IV formulation of rolapitant submitted
TSRO: 43.30 (+0.83)

TESARO Announces Submission of Investigational New Drug Application for Anti-TIM-3 Antibody TSR-022 to the U.S. FDA
GlobeNewswire - Mon Apr 25, 7:05AM CDT
TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the submission of an Investigational New Drug (IND) Application for TSR-022 to the U.S. Food and Drug Administration. TSR-022 is a monoclonal antibody drug candidate targeting TIM-3.
TSRO: 43.30 (+0.83)

TESARO to Announce First Quarter 2016 Financial Results on May 5, 2016
GlobeNewswire - Thu Apr 21, 3:05PM CDT
TESARO, Inc. (NASDAQ:TSRO) will announce its first quarter 2016 financial results on Thursday, May 5, 2016, after the close of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast at 4:15 p.m. ET on May 5, 2016 to discuss the Company's operating results in greater detail, as well as the status of its development programs and the VARUBI(R) launch.
TSRO: 43.30 (+0.83)

TESARO Announces Global Prostate Cancer Collaboration and Licensing Agreement With Janssen
GlobeNewswire - Wed Apr 06, 6:00AM CDT
-- Janssen to develop and commercialize niraparib for patients with prostate cancer worldwide, except in Japan
TSRO: 43.30 (+0.83)

TESARO Announces Appointment of Dr. Kavita Patel to Board of Directors
GlobeNewswire - Mon Apr 04, 7:00AM CDT
TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the appointment of Kavita Patel, M.D., M.S., F.A.C.P. to the Company's Board of Directors. Dr. Patel has served as a Senior Fellow at The Brookings Institution, as well as a practicing physician at Johns Hopkins since January 2011.
TSRO: 43.30 (+0.83)

TESARO Announces Enrollment of First Patient in Phase 1 Clinical Trial of TSR-042
GlobeNewswire - Tue Mar 29, 7:08AM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced it has dosed the first patient in a Phase 1, dose-escalation study of its lead anti-PD-1 monoclonal antibody candidate, TSR-042. Following identification of a dose and schedule for TSR-042, the trial is planned to expand into tumor specific cohorts.
TSRO: 43.30 (+0.83)

TESARO and MD Anderson Cancer Center Announce Immuno-Oncology Collaboration and Exclusive License Agreement
GlobeNewswire - Tue Mar 29, 7:08AM CDT
-- Goal to identify novel small molecule therapeutics against undisclosed immuno-oncology targets
TSRO: 43.30 (+0.83)

TESARO Announces Validation of Marketing Authorisation Application for Oral Rolapitant by the European Medicines Agency
GlobeNewswire - Wed Mar 23, 8:00AM CDT
TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the Marketing Authorisation Application (MAA) for oral rolapitant has been submitted to and validated by the European Medicines Agency. Rolapitant is a substance P/neurokinin-1 (NK-1) receptor antagonist that is marketed by TESARO in the United States under the brand name VARUBI(R).
TSRO: 43.30 (+0.83)

Ally Bridge Group (ABG) Completes Its Investment in TESARO, Inc. (TSRO)
PR Newswire - Mon Mar 21, 10:25AM CDT
Ally Bridge Group ("ABG", a global healthcare-focused investment group, announced that it has completed an equity investment in TESARO, Inc. (NASDAQ:TSRO), an oncology-focused, commercial-stage biopharmaceutical company headquartered in Waltham, Massachusetts, USA. This investment was made as part of a private placement of 4.4 million shares of TSRO common stock that closed on March 17, 2016, resulting in gross proceeds of $155 million.
TSRO: 43.30 (+0.83)

TESARO Announces Closing of $155 Million Private Placement
GlobeNewswire - Fri Mar 18, 3:05PM CDT
TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, announced today it has completed its previously announced private placement of 4.4 million shares of common stock at a price of $35.19 per share. This transaction resulted in total gross proceeds to the Company of approximately $155 million. TESARO intends to use the proceeds from the financing primarily to support the development of its product pipeline and for general corporate purposes.
TSRO: 43.30 (+0.83)

TESARO Submits New Drug Application for Intravenous Rolapitant to the U.S. Food and Drug Administration
GlobeNewswire - Mon Mar 14, 7:05AM CDT
TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has submitted the New Drug Application (NDA) for an intravenous (IV) formulation of rolapitant to the U.S. Food and Drug Administration (FDA).
TSRO: 43.30 (+0.83)

3 Reasons Opko Health Stock Could Rise
Cory Renauer, The Motley Fool - Motley Fool - Tue Mar 08, 11:25AM CST
Image source: Opko Health. While the broad market dipped and rebounded -- mostly -- this year, Opko Health stock has been on a virtual roller-coaster ride. In early February, shares of the diagnostics and pharmaceutical company fell more than...
TSRO: 43.30 (+0.83), OPK: 9.55 (+0.19), PFE: 34.34 (-0.13)

3 Can't-Miss Quotes From Phillip Frost Regarding Opko Health's Future
Todd Campbell, The Motley Fool - Motley Fool - Sun Mar 06, 8:19AM CST
SOURCE: OPKO HEALTH. Iconic healthcare entrepreneur Phillip Frost is at it again. After serving for years as Teva Pharmaceuticals ' chairman, the billionaire healthcare investor is in the top seat at Opko Health , and he's knee-deep transforming...
TSRO: 43.30 (+0.83), OPK: 9.55 (+0.19), TEVA: 51.11 (-0.08)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 362

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 39

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 481

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 298

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 527

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 419

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 583

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 90

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 407

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading

Top 5 Most Recently Viewed Articles

Sentry Insurance Company Announces Strategic Acquisition Plans

Updated Category News Views 205

Insights into Sentry Insurance Company's Acquisition Strategy OLDWICK, N.J.--AM Best has announced that the Credit Ratings of Sentry Insurance Company, along with its subsidiaries—collectively known as Sentry—will stay stable after the recent news of their acquisition of The General from American Family Insurance Group. This deal includes Permanent General Assurance...

Continue Reading
Growth Outlook for the Automotive Horn System Market

Updated Category News Views 165

Overview of the Automotive Horn System Market Wilmington, Delaware - A recent market analysis reveals a significant shift in the automotive horn system industry. The report estimates that the market, currently valued at $0.7 billion, is projected to grow to $1.8 billion by the end of the forecast period in 2033, achieving an impressive compound annual growth rate (CAGR)...

Continue Reading
Payoneer Completes Warrant Purchase Offer and Amendments

Updated Category News Views 105

Payoneer Completes Warrant Purchase Offer and Consent Solicitation Payoneer Global Inc. (NASDAQ: PAYO), a financial technology company serving businesses worldwide, has completed its cash offer to buy outstanding Warrants at $0.78 each. The move is designed to simplify Payoneer’s capital structure and give warrant holders a clear cash alternative, while keeping the...

Continue Reading
The Aesthetic Medicine Market's Future: Key Trends to Watch

Updated Category News Views 251

Sales Expectations for the Aesthetic Medicine Market The global aesthetic medicine market was estimated at US$ 83.12 billion recently, with projections indicating a remarkable potential to rise to US$ 233.67 billion by the year 2033. This growth is anticipated at a compound annual growth rate (CAGR) of 12.17% from 2025 through to 2033. Impact of Technological Innovations...

Continue Reading
Bauducco's Florida Expansion Boosts U.S. Manufacturing

Updated Category News Views 74

New Facility Marks a Strategic Shift for Bauducco Imagine three generations crafting baked goods, and then picture this: Bauducco, the Brazilian icon for snacks like wafer cookies and Panettone, boldly stepping onto the U.S. manufacturing stage. They have just swung wide the doors of their largest stateside factory, right in Zephyrhills, Florida. They're not here to...

Continue Reading